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Abstract
The median survival in glioblastoma is just over a year, with no standard second-line therapy. Ipilimumab is an immune checkpoint inhibitor that activates the
anti-tumour immune response by cytotoxic T-lymphocyte antigen-4 blockade. There is signiﬁcant evidence supporting its role in the treatment of malignant
melanoma, including in patients with brain metastases. The addition of the anti-angiogenesis agent, bevacizumab, seems to offer additional beneﬁt and limit the
immune-related side-effects of ipilimumab in melanoma. To date there have been no clinical trials investigating this combination in glioblastoma. In this single
practice case series, 20 patients with glioblastomawere consented for and treated with ipilimumab and bevacizumab in combination. Safety, tolerability and the
response to treatment were reviewed for all patients. Three patients were treated after palliative ﬁrst-line radiotherapy, one patient after ﬁrst-line chemo-
radiation and 16 patients were treated with recurrent disease. Sixty-ﬁve per cent of patients completed four cycles of 3 weekly ipilimumab therapy, admin-
istered with 2 weekly bevacizumab. Radiographic responses for patients with recurrent disease were evaluated by Response Assessment in Neuro-oncology
(RANO) criteria; 31% of patients showed a partial response, 31% had stable disease and 38% had disease progression. The treatment combination was well
tolerated, with treatment terminated before completion due to adverse events in two patients. Autoimmune toxicity was manageable with systemic cortico-
steroid therapy. Ipilimumab and bevacizumab in combination show promising activity with a predictable and manageable toxicity proﬁle, warranting further
clinical studies.
 2016 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Glioblastoma is the most commonly occurring primary
brain tumour. It remains associated with a very poor
prognosis and amedian survival of just over a year [1]. First-
line treatment is surgical resection followed by radio-
therapy and temozolomide chemotherapy [2]. There is no
standard second-line therapy and most patients either
receive a lomustine-containing chemotherapy regimen or
enter clinical trials.
Ipilimumab is a fully humanised IgG1 monoclonal anti-
body that potentiates the anti-tumour T-cell response by
blocking the cytotoxic T-lymphocyte antigen-4, a criticalAuthor for correspondence: P. Mulholland, Cancer Division, University
College London Hospital, First Floor Central, 250 Euston Road, Fitzrovia,
London NW1 2PG, UK.
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creativecommons.org/licenses/by-nc-nd/4.0/).negative regulator (checkpoint) of T-cells. To date, the ma-
jority of clinical experience and efﬁcacy data for ipilimumab
are in the setting of metastatic malignant melanoma [3], for
which it has become an established treatment leading to
durable long-term survival in a subset of patients with
advanced disease [4]. Ipilimumab has also shown responses
in patients with malignant melanoma and brain metastases
[5], highlighting efﬁcacy within the central nervous system.
Ipilimumab has been administered safely alongside
bevacizumab in melanoma, with evidence of synergistic
efﬁcacy and manageable toxicity when compared with
ipilimumab alone [6]. Bevacizumab is a humanised mono-
clonal antibody that targets vascular endothelial growth
factor. Studies have shown bevacizumab to bewell tolerated
in both newly diagnosed and recurrent glioblastoma, with
evidence of anti-tumour and anti-oedema activity [7].
Although the addition of bevacizumab to standard therapy
in newly diagnosed glioblastoma shows no improvementsd. This is an open access article under the CC BY-NC-ND license (http://
T. Carter et al. / Clinical Oncology 28 (2016) 622e626 623in overall survival [8], there is some evidence that it can
preserve quality of life and performance status [9]. To date,
there have been no clinical trials investigating the combi-
nation of ipilimumab and bevacizumab in glioblastoma. We
describe here the safety and tolerability of a treatment
regimen containing ipilimumab and bevacizumab.Patients and Methods
Twenty patients with glioblastoma who had previously
received treatment with ﬁrst-line therapy as tolerated were
consented for treatment with an off-label regimen
combining ipilimumab and bevacizumab; granulocyte-
colony stimulating factor was included to boost peripheral
white cell counts, reduce chemotherapy-induced myelosu-
pression and potentiate anti-tumour immunity [10]. Treat-
ment was given either in place of or alongside oral palliative
chemotherapy. Nineteen patients had conﬁrmed World
Health Organization grade IV disease and one patient had a
recurrent astrocytoma (grade II), radiologically consistent
with grade IV disease. Sixteen patients were treated after
disease progression; two of these patients had completed
ﬁrst-line chemoradiotherapy within 3 months. Three of the
remaining patients were treated after ﬁrst-line short-
course radiotherapy, and one was treated after standard
chemoradiotherapy. All patients who began treatment with
the regimen were included in the analysis. Patient de-
mographics and biomarkers including methylguanineTable 1







1 Glioblastoma 10% Negative
2 Glioblastoma Methylated Negative





5 Astrocytoma 10% Negative
6 Gliosarcoma Unmethylated Negative
7 Glioblastoma Unmethylated Negative
8 Glioblastoma Methylated Negative
9 Glioblastoma 10% Negative
10 Glioblastoma Unmethylated Negative
11 Glioblastoma Unmethylated Negative
12 Glioblastoma Unmethylated Negative
13 Glioblastoma Unmethylated Negative
14 Glioblastoma 5% Negative
15 Glioblastoma Unmethylated Negative
16 Glioblastoma 10% Negative
17 Glioblastoma Not available Not available
18 Glioblastoma 10% Negative
19 Glioblastoma Methylated Negative
20 Glioblastoma Not available Not available
MGMT, methylguanine methyltransferase; IDH-1, isocitrate dehydrogemethyltransferase promoter methylation and isocitrate
dehydrogenase-1 mutation status are shown in Table 1.
Ipilimumab was dosed at 3 mg/kg body weight every 3
weeks for four cycles followed by maintenance therapy
every 12 weeks. Each ipilimumab dose was followed by
granulocyte-colony stimulating factor within 24 h.
Bevacizumab was dosed at 10 mg/kg, administered every
2 weeks. Patients were assessed before each treatment
with a full clinical review and standard blood tests,
including thyroid function. Interim 6 weekly magnetic
resonance imaging scans were carried out to determine
disease response. Adverse event data were recorded and
analysed to determine safety and tolerability.
Radiographic responses were assessed using the Response
Assessment in Neuro-oncology (RANO) criteria [11].Results
Between January 2014 and April 2015, 20 patients began
treatment with four 3 weekly cycles of ipilimumab in
addition to 2 weekly bevacizumab. Of these patients, 13
patients (65%) completed all four cycles. In the seven pa-
tients who did not complete four cycles, the reasons were
dose-limiting toxicity (two patients) and clinical deterio-
ration (ﬁve patients). Of the 13 patients who completed all
four standard cycles, nine (69%) proceeded to maintenance
therapy. All patients underwent interim magnetic reso-
nance imaging 6 and 12 weeks after the start of treatment
to determine the response to treatment, with responsesus Gender Age at
treatment
First-line treatment received
Female 54 Short-course radiotherapy
Female 46 Short-course radiotherapy
Male 60 Short-course radiotherapy
Male 23 Radiotherapy with TMZ
Female 31 Radiotherapy alone 7 cycles TMZ
Female 38 Chemoradiotherapy 5 cycles TMZ
Female 48 Chemoradiotherapy 2 cycles TMZ
Male 55 Chemoradiotherapy 6 cycles TMZ
Male 45 Chemoradiotherapy 12 cycles TMZ
Male 23 Chemoradiotherapy 6 cycles TMZ
Male 35 Chemoradiotherapy 8 cycles TMZ
Female 28 No radiotherapy
Female 52 Chemoradiotherapy 4 cycles TMZ
Male 58 Chemoradiotherapy 6 cycles TMZ
Male 40 Chemoradiotherapy 0 cycles TMZ
Male 69 Chemoradiotherapy 9 cycles TMZ
Male 66 Chemoradiotherapy 6 cycles TMZ
Male 69 Chemoradiotherapy 7 cycles TMZ
Female 46 Chemoradiotherapy 6 cycles TMZ
Male 55 Chemoradiotherapy 6 cycles TMZ
nase-1; TMZ, temozolomide.
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recurrent disease. Five patients (31%) had a partial response
to treatment, two of whom had over a 90% reduction
(Figure 1). Five patients (31%) had stable disease; the
remaining six patients (38%) had disease progression. One
patient treated after palliative short-course radiotherapy
also had a greater than 90% response to treatment (Figure 1,
Patient 1). Performance status was maintained or improved
during treatment for 12 of the 14 patients (85%) who either
responded or had stable disease. Table 2 shows the number
of cycles of treatment received by patients, together with
the reported radiographic responses. Steroid doses were
also collected (data not shown) to assist with reporting
treatment responses to RANO criteria. For those patients
with recurrent disease, 11 patients (69%) remained alive,
four of whom (25%) were progression-free 6 months after
treatment start date. Survival data continue to be collected
for all patients.
Adverse events are shown in Table 3. The most
commonly seen adverse events were fatigue (40%, eight
patients) and diarrhoea (30%, six patients). One patient
suffered an intracerebral bleed and two further patients
were diagnosed with pulmonary emboli, events attribut-
able to disease. There were no grade 4 adverse events
observed. Treatment was terminated early due to grade 2
rash (one patient) and grade 2 arthritis (one patient). Three
patients experienced grade 3 abscess formation (dental,
uterine, diverticular), all of whom were managed surgi-
cally. Although six patients experienced diarrhoea, none
stopped treatment early and symptoms were manageable
with corticosteroids. There were no diagnoses of
endocrinopathies.Fig 1. Corresponding images from baseline and 6 week scan for thos
Assessment in Neuro-oncology (RANO) criteria.Discussion
Our observations on 20 patients showed that a combi-
nation of ipilimumab and bevacizumab is well tolerated in
patients with glioblastoma. To the best of our knowledge
this is the largest glioblastoma patient series reported to
date with this treatment regimen. The manageable toxic-
ities reported are supported by the results of a phase I trial
of 46 patients withmetastatic malignant melanoma [6]. Our
results are also supported by two abstracts published by
other groups reporting use of ipilimumab in glioblastoma.
In these small studies, all patients (5/5) experienced toxicity
when treated with ipilimumab alone [12], whereas the
combination of ipilimumab and bevacizumabwas less toxic,
with 1/10 patients experiencing signiﬁcant immune toxicity
events [13].
The rationale behind the co-administration of bev-
acizumab with ipilimumab in our patients was to preserve
quality of life, limit corticosteroid requirements and
modulate toxicity. However, there may also be additional
beneﬁt from bevacizumab due to its positive effects in
modulation of the immune response to tumours. Vascular
endothelial growth factor downregulates the immune sys-
tem by inhibiting the maturation of dendritic cells and T-
cells, and controlling the endothelial trafﬁcking of T-cells;
processes that are reversed by bevacizumab [14]. There is
also an increasing body of pre-clinical work supporting a
role for immune checkpoint inhibitors in the treatment of
glioblastoma [15,16]. A number of in vivo studies have
shown the efﬁcacy of ipilimumab alone [17] and in combi-
nation with other treatments [18], including other check-
point inhibitors [19].e patients with partial radiographic responses based on Response
Table 2
Number of treatment cycles received, number of months after diagnosis to the start of treatment and radiographic responses seen at 6 and
12 weeks

















1 2 4 Yes Temozolomide Partial response* Partial response*
2 2 2 No None Stable disease* Stable disease*
3 3 4 No Temozolomide Stable disease* Stable disease*
4 3 4 Yes Temozolomide Stable disease* Stable disease*
Recurrent disease
5 1y 2 No Lomustine Partial response Stable disease
6 12 2 No Lomustine Progression Not done
7 4 4 Yes Temozolomide Stable disease Stable disease
8 32 4 Yes Lomustine Partial response Partial response
9 15 4 No None Progression Progression
10 14 4 Yes None Partial response Stable disease
11 9 4 Yes None Stable disease Progression
12 3 4 Yes None Stable disease Stable disease
13 8 4 Yes Temozolomide Stable disease Stable disease
14 17 4 Yes None Partial response Stable disease
15 4 4 No Temozolomide Progression Progression
16 18 4 Yes Lomustine Stable disease Stable disease
17 19 2 No Lomustine Progression Progression
18 10 2 No Lomustine Progression Not done
19 34 2 No Lomustine Partial response Stable disease
20 11 1 No Lomustine Stable disease Not done
* Although scan responses are reported for those patients treated immediately after standard therapy, these data were excluded from the
overall analysis as they had not progressed at the time of starting this regimen.
y Patient 5 was treated within 1 month of a radiological diagnosis of glioblastoma, after previous treatment for grade II disease.
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mumab in glioblastoma, clinical experience with the drug
continues to develop. Ipilimumab has been investigated in
combinationwith a second checkpoint inhibitor nivolumab,
which targets the programmed death receptor 1. Although
there is evidence that these two drugs show synergy in
melanoma [20,21], this has so far not been found in glio-
blastoma (NCT02017717) [22], where the combination
conferred no additional beneﬁt and greatly increased the
incidence of immune toxicity when compared with nivolu-
mab alone. A second phase I safety study is planned inves-
tigating ipilimumab and nivolumab in combination with
temozolomide for glioblastoma (NCT02311920). As a mon-
otherapy, nivolumab shows efﬁcacy in melanoma [23], lungTable 3
Observed adverse events in all patients (regardless of causality)
Adverse event Grade Total number (% patients)
1 2 3
Fatigue 8 0 0 8 (40%)
Diarrhoea 2 3 1 6 (30%)
Abscess formation 0 0 3 3 (15%)
Rash 0 1 0 1 (5%)
Arthritis 0 1 0 1 (5%)
Perianal ﬁstula 0 1 0 1 (5%)
Intracerebral bleed 0 0 1 1 (5%)
Pulmonary embolism 0 0 2 2 (10%)cancer [24] and renal cell carcinoma [25] and is currently
being investigated in a phase III trial in glioblastoma
(NCT02017717). A second anti-programmed death receptor
1 checkpoint inhibitor, pembrolizumab, is clinically
approved for use in melanoma [26,27] and clinical trials in a
variety of tumours are either open or registered, including
investigating pembrolizumab in combination with bev-
acizumab for recurrent glioblastoma (NCT02337491).
Ipilimumab, nivolumab and pembrolizumab have
established immune checkpoint inhibition in clinical prac-
tice, and there are more immune checkpoint inhibitors in
pre-clinical development. The potential for targeting im-
mune checkpoints continues to grow [28,29] and on-going
research into the mechanisms of action of these drugs
suggest that they could also augment the effect of radio-
therapy in some cancers [30], including glioblastoma [31].Conclusions
The results shown here show that 31% of patients with
recurrent disease had a partial radiographic response to
treatment based on RANO criteria, and a further 31% had
stable disease. Treatment was well tolerated, with treat-
ment terminated before completion due to adverse events
in two patients. Five other patients experienced toxicities at
grade 2 or above, which could be attributed to the drug
combination. All immune-related toxicities were manage-
able with corticosteroids.
T. Carter et al. / Clinical Oncology 28 (2016) 622e626626The data presented in this patient series is non-
randomised and involves small patient numbers. Howev-
er, the results warrant investigation in formal prospective
clinical trials, both in newly diagnosed and recurrent dis-
ease. The recently reported immunotherapy-RANO (iRANO)
guidelines may usefully contribute to future analysis in
clinical trials [32]. In addition, there remains a need for
further pre-clinical research towards a better understand-
ing of the biological basis for response to checkpoint inhi-
bition. Data from current and futurework in pre-clinical and
clinical settings will be vital to stratify patients to the most
appropriate therapy for this devastating condition.Acknowledgements
Work supported by the EU Seventh Framework Pro-
gramme (FP7) (Dartrix EC GRANT: 278580), the University
College Hospital/University College London (UCH/UCL)
Biomedical Research Centre and The National Brain Appeal.References
[1] Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus
concomitant and adjuvant temozolomide for glioblastoma.
New Engl J Med 2005;352:987e996.
[2] Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy
with concomitant and adjuvant temozolomide versus radio-
therapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10:459e466.
[3] Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with
ipilimumab in patients with metastatic melanoma. New Engl J
Med 2010;363:711e723.
[4] Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of
long-term survival data from phase II and phase III trials of
ipilimumab in unresectable or metastatic melanoma. J Clin
Oncol 2015;56:736.
[5] Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in pa-
tients with melanoma and brain metastases: an open-label,
phase 2 trial. Lancet Oncol 2012;13:459e465.
[6] Hodi FS, Lawrence D, Lezcano C, et al. Bevacizumab plus ipi-
limumab in patients with metastatic melanoma. Cancer
Immunol Res 2014;2(7):632e642.
[7] Norden A, Young G, Setayesh K, et al. Bevacizumab for
recurrent malignant gliomas. Efﬁcacy, toxicity, and patterns of
recurrence. Neurology 2008;70:779e787.
[8] Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial
of bevacizumab for newly diagnosed glioblastoma. New Engl J
Med 2014;370:699e708.
[9] Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radi-
otherapyetemozolomide for newly diagnosed glioblastoma.
New Engl J Med 2014;370:709e722.
[10] Vacchelli E, Aranda F, Obrist F, et al. Trial watch: immunosti-
mulatory cytokines in cancer therapy. Oncoimmunology
2014;3:e29030.
[11] Wen PY, Macdonald DR, Reardon DA, et al. Updated response
assessment criteria for high-grade gliomas: response assess-
ment in neuro-oncology working group. J Clin Oncol
2010;28:1963e1972.
[12] Hu JL, Sharma P, Yu J, Black KL, Rudnick JD. Ipilimumab for
recurrent glioblastoma: a single-institution case series. ASCO
Annual Meeting Proceedings 2014, e13010.[13] Schaff LR, Lassman AB, Goldlust SA, et al. Ipilimumab for
recurrent glioblastoma (GBM). Neuro-oncology 2014;16:v90.
[14] Elamin YY, Rafee S, Toomey S, Hennessy BT. Immune effects of
bevacizumab: killing two birds with one stone. Cancer
Microenvironment 2014;8(1):1e7.
[15] Klein S, Gokhale P, Jones K, et al. Immune checkpoint blockade
activates effective anti-tumor immunity in an orthotopicmodel
of glioblastoma (VAC12P.1119). J Immunol 2015;194:213.
[16] Reardon D, Gokhale P, Ligon K, et al. Immune checkpoint
blockade for glioblastoma: preclinical activity of single agent
and combinatorial therapy. Neuro-oncology 2014;16:v116.
[17] Fecci PE, Ochiai H, Mitchell DA, et al. Systemic CTLA-4
blockade ameliorates glioma-induced changes to the CD4þ
T cell compartment without affecting regulatory T-cell func-
tion. Clin Cancer Res 2007;13:2158e2167.
[18] Vom Berg J, Vrohlings M, Haller S, et al. Intratumoral IL-12
combined with CTLA-4 blockade elicits T cellemediated gli-
oma rejection. J Exp Med 2013;210:2803e2811.
[19] Wainwright DA, Chang AL, Dey M, et al. Durable therapeutic
efﬁcacy utilizing combinatorial blockade against IDO, CTLA-4,
and PD-L1 in mice with brain tumors. Clin Cancer Res
2014;20:5290e5301.
[20] Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus
ipilimumab in advanced melanoma. New Engl J Med
2013;369:122e133.
[21] Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivo-
lumab and ipilimumab or monotherapy in untreated mela-
noma. New Engl J Med 2015;373:23e34.
[22] Sampson J, Vlahovic G, Desjardins A, et al. Randomized phase
IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538)
alone or in combinationwith ipilimumab versus bevacizumab
in patients (pts) with recurrent glioblastoma (GBM). J Clin
Oncol 2014;32:TPS2101.
[23] Topalian SL, Sznol M, McDermott DF, et al. Survival, durable
tumor remission, and long-term safety in patients with
advanced melanoma receiving nivolumab. J Clin Oncol
2014;32:1020e1030.
[24] Brahmer JR, Horn L, Gandhi L, et al. Nivolumab (anti-PD-1, BMS-
936558, ONO-4538) in patients (pts) with advanced non-small-
cell lung cancer (NSCLC): survival and clinical activity by sub-
group analysis. ASCO Annual Meeting Proceedings 2014, 8112.
[25] Motzer R, Escudier B, McDermott D, et al. Nivolumab versus
everolimus in advanced renal-cell carcinoma. N Engl J Med
2015;373(19):1803e1813.
[26] Robert C, Schachter J, Long GV, et al. Pembrolizumab versus
ipilimumab in advanced melanoma. N Engl J Med
2015;372(26):2521e2532.
[27] NICE. Pembrolizumab for treating advanced melanoma after
disease progression with ipilimumab. National Institute for
Health and Care Excellence (NICE) technology appraisal
guidance. TA357. Available at:, http://www.nice.org.uk; 2015.
[28] Pennock GK, Chow LQ. The evolving role of immune checkpoint
inhibitors in cancer treatment. Oncologist 2015;20:812e822.
[29] Webster RM. The immune checkpoint inhibitors: where are
we now? Nat Rev Drug Disc 2014;13(12):883e884.
[30] Pilones KA, Vanpouille-Box C, Demaria S. Combination of
radiotherapy and immune checkpoint inhibitors. Semin Radiat
Oncol 2015;25:28e33.
[31] Belcaid Z, Phallen JA, Zeng J, et al. Focal radiation therapy com-
bined with 4-1BB activation and CTLA-4 blockade yields long-
term survival and a protective antigen-speciﬁc memory
response inamurinegliomamodel.PloSone2014;9(7):e101764.
[32] Okada H, Weller M, Huang R, et al. Immunotherapy response
assessment in neuro-oncology: a report of the RANO working
group. Lancet Oncol 2015;16:e534ee542.
